Ajanta Pharma reported stellar Q2 beating our estimates on the operating performance. Top-line grew 8% YoY, in-line with our estimate, driven by US and branded Africa business. Other geographies including India were muted. However, lower opex aided margins at 38.3% (up 490 bps QoQ and 1,070 bps YoY), way higher than our estimates. While the same is expected to taper as activities resume in subsequent quarters,...
Apollo tyre(APTY) reported strong all-round performance in Q2FY21 driven by 1) strong revenue traction in replacement market (+18% YoY for TBR and 11% YoY for PCR) benefited from supply issues faced by its competitors and ban on import of Chinese tyres; 2) enhanced product mix (replacement share 74% vs 67%) and 3) RM tailwinds. Company has gained significant market share across segments (500bps for PCR and 350bps for T&B;) and regions. EBITDA grew 61% YoY to Rs 6.95bn with expanded margin at 16.2%...
83% of the company's portfolio, related to health, hygiene and value for money, delivered 17% sales growth during the quarter. HI category posted mere 4% growth, was a negative surprise, especially considering 22% growth reported by Jyothy Lab in the same segment. We have upward revised our FY21E and FY22E EPS at Rs 17.1 and Rs 18.3, respectively and introduced FY23E EPS estimate at Rs 19.6. We believe that the recent correction in the price makes the stock attractive at CMP. Valuing GCPL at 38x FY23E earnings to arrive at a TP...
Jamna Auto's posted decent numbers in Q2FY21 amid challenging environment. EBIDTA grew 3% YoY to Rs 166mn with expanded margin of 8.9% (+149bps YoY), led by cost control measures and richer mix (increase in mix for replacement revenue). Capex in H1FY21 was Rs 34mn, CFO stood at Rs 1.43bn and the company generated FCF of Rs 1.39bn driven by efficient working capital management. The company has also reduced its net debt to Rs...
EBITDA, consequently saw a strong growth of 73.6% YoY to Rs 5.82bn (D.est: Rs 4.17bn) led by gross margin expansion and low Opex (up 1.4% YoY to Rs 2.23bn). Power and Fuel/Employee costs were at a...
Asahi India Glass (AIS) printed an impressive earning performance in 2Q. EBITDA grew 13% YoY to Rs.1.2bn with expanded margin at 19.1% (+235bps YoY) led by lower fuel cost and cost control measures. EBIT margin for Automotive glass expanded by 175bps YoY to 14.4% and for Architecture glass by 314bps YoY to 17.3%. We expect the company to be a key beneficiary of revival in the volume of Automotive and Architectural glass segments. Moreover, strong traction in aftermarket business will also aid profitability. In the...
KEC has reported Q2 revenue, EBIDTA and PAT better than estimates (Refer Exhibit 1), with supply chain and labor levels back to normal. Order inflow for YTDFY21 was Rs43.7bn, with 41% domestic orders. Its...
Sales for Q2FY21 came in flat at Rs18.8bn, largely in line with our estimates, as company successfully restored labor availability and normalcy of supply chain; majority of projects are currently operating at pre-COVID levels. EBITDA came in flat at Rs2bn while EBITDA margins were stable at 10.7%. The company has an order book of Rs.123bn with a split of ~40% orders from O&G; and Rail business The company is looking at an ordering pipeline of Rs140-150bn in the domestic space. Along with Oil & Gas and Railways, it is targeting a full...
Indian Hotels (IHCL) Q2FY21 revenue decline at 75% YoY was higher than our estimate of 69%. Yet, EBITDA/APAT was ahead of estimates led by higher than expected costs savings. IHCL's net debt has increased sharply by Rs 10.3bn (Rs 6.14bn in Q2) to Rs 29.4bn. We remain positive on IHCL led by its strong brand recall and footprint across segments, asset-light approach, monetization of non-core assets, focus on driving alternate revenue streams, repositioning Ginger in lean luxury segment and efficient costs management....
$22mn (DE at $20mn) as the strong bookings in Licence-based deals in ERP segment (up 18% QoQ) boosted revenue recognition in Q2. Company won new orders worth US$26.5mn in Q2FY21 up 24% on QoQ basis, coming back to its pre-Covid run rate. Unexecuted order book stood at US$164mn (2x revenue), providing good revenue visibility. Qualified pipeline stands at $211mn while ARR at $28mn (37% of rev). EBIDTA margins declined 355bps QoQ on account on increased subcontracting in Q2 as well as unfavorable Fx swing of almost 1mn$. Adjusted for Fx EBIDTA margins improved by 170bps QoQ at 28.6%....
